NCT00280475

Brief Summary

The aim of this study is to evaluate non-inferiority of salvage stereotactic radiosurgery (SRS) in the patients who received surgical resection for brain metastases in comparison with postoperative whole brain radiation therapy (WBRT).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
270

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Jan 2006

Longer than P75 for phase_3

Geographic Reach
1 country

21 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2006

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

January 20, 2006

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 23, 2006

Completed
6.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2013

Completed
Last Updated

September 22, 2016

Status Verified

September 1, 2016

Enrollment Period

7 years

First QC Date

January 20, 2006

Last Update Submit

September 20, 2016

Conditions

Keywords

Randomized Controlled TrialsBrain Neoplasms/SecondaryBrain Neoplasms/RadiotherapyRadiosurgery

Outcome Measures

Primary Outcomes (1)

  • overall survival

    During the study conduct

Secondary Outcomes (3)

  • proportion of performance status (PS) preservation

    During the study conduct

  • proportion of mini-mental status examination (MMSE) preservation

    During the study conduct

  • adverse events

    During the study conduct

Study Arms (2)

1

ACTIVE COMPARATOR

Device: Whole brain radiation therapy arm

Device: Whole brain radiation therapy arm

2

EXPERIMENTAL

Device: Salvage stereotactic radiosurgery arm

Device: Salvage stereotactic radiosurgery arm

Interventions

Whole brain radiation therapy arm

1

Salvage stereotactic radiosurgery arm

2

Eligibility Criteria

Age20 Years - 79 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • one to four brain metastases with a maximum diameter of 3 cm or more for the largest lesion and additional lesions not exceeding 3 cm in diameter
  • all brain metastases localized within cerebrum or cerebellum
  • before surgical resection for brain metastasis, PS is 0-2, or 3 by cerebral nerve compression neurological deficits
  • surgical resection for the largest brain metastases has achieved
  • after surgical resection, four or fewer (0-4) residual lesions with maximum diameter under 3 cm
  • histologically proven non-small cell carcinoma, breast cancer or colorectal cancer
  • primary lesion and the other metastases (i.e. lung, liver, bone metastases except for brain) is consider to be controlled
  • an age of 20-79 years
  • no prior surgery or irradiation for brain
  • adequate organ function
  • written informed consent(If signing in consent form is difficult for the patient due to paralysis, signing by the family in place of the patient is permitted)

You may not qualify if:

  • synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ or mucosal cancer
  • pregnant or breast-feeding women
  • severe mental disease
  • allergic to gadolinium contained contrast agents

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (21)

Nagoya University School of Medicine

Nagoya,Showa-ku,Tsurumai-cho,65, Aichi-ken, 466-8550, Japan

Location

Chiba University, Graduate School of Medicine

Chiba,Chuo-ku,Inohana,1-8-1, Chiba, 260-8670, Japan

Location

Ehime University Hospital

Shitsukawa,Toon, Ehime, 791-0295, Japan

Location

Kyushu University Hospital

Higashi-ku,Maidashi,3-1-1, Fukuoka, 812-8582, Japan

Location

Hokkaido University Hospital

North-14 West-5 Kita-ku,Sapporo, Hokkaido, 060-8648, Japan

Location

Nakamura Memorial Hospital

South-1,West-14,Chuou-ku,Sapporo, Hokkaido, 060-8570, Japan

Location

Iwate Medical University

Morioka,Uchimaru,19-1, Iwate, 020-8505, Japan

Location

St.Marianna University School of Medicine

Kawasaki,Miyamae-ku,Sugao,2-16-1, Kanagawa, 216-8511, Japan

Location

Kumamoto University Medical School

Kumamoto,Honjo,1-1-1, Kumamoto, 860-8556, Japan

Location

Kyoto University Hospital

Kyoto,Sakyo-ku,Syogoinkawara,54, Kyoto, 606-8507, Japan

Location

Tohoku University Hospital

Sendai,Aoba-ku,Seiryo-machi,1-1, Miyagi, 980-8574, Japan

Location

Niigata University Medical and Dental Hospital

Niigata,Asahimachi-dori,1-754, Niigata, 951-8520, Japan

Location

Saitama Medical School Hospital

Iruma-gun,Moroyama-machi,Morohongo,38, Saitama, 350-0495, Japan

Location

The University of Tokyo Hospital

Bunkyo-ku,Hongo,7-3-1, Tokyo, 113-8655, Japan

Location

National Cancer Center Hospital

Chuo-ku,Tsukiji,5-1-1, Tokyo, 104-0045, Japan

Location

Teikyo University School of Medicine

Itabashi-ku,Kaga,2-11-1, Tokyo, 173-8605, Japan

Location

Kyorin University School of Medicine

Mitaka,Shinkawa,6-20-2, Tokyo, 181-8611, Japan

Location

Tokyo Women's Medical University

Shinjuku-ku,Kawada-cho,8-1, Tokyo, 162-8666, Japan

Location

Keio University Hospital

Shinjuku-ku,Shinanomachi,35, Tokyo, 160-8582, Japan

Location

Yamagata University Faculty of Medicine

Yamagata City,Iida-nishi, 2-2-2, Yamagata, 990-585, Japan

Location

University of Yamanashi Faculty of Medicine

Nakakoma,Tamaho,Shimokato,1110, Yamanashi, 409-3898, Japan

Location

Related Publications (1)

  • Simeoli C, Di Paola N, Stigliano A, Lardo P, Kearney T, Mezosi E, Ghigo E, Giordano R, Mariash CN, Donegan DM, Feelders RA, Hand AL, Araque KA, Moraitis AG, Pivonello R. Relacorilant or surgery improved hemostatic markers in Cushing syndrome. J Endocrinol Invest. 2025 Mar;48(3):671-680. doi: 10.1007/s40618-024-02468-2. Epub 2024 Sep 21.

Related Links

MeSH Terms

Conditions

Brain NeoplasmsNeoplasm Metastasis

Condition Hierarchy (Ancestors)

Central Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNeoplasmsBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Takamasa Kayama, MD, PhD

    Yamagata University Faculty of Medicine

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
JCOG Data Center

Study Record Dates

First Submitted

January 20, 2006

First Posted

January 23, 2006

Study Start

January 1, 2006

Primary Completion

January 1, 2013

Study Completion

January 1, 2013

Last Updated

September 22, 2016

Record last verified: 2016-09

Locations